It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
DNA-Damage Response (DDR) proteins are crucial for maintaining the integrity of the genome by identifying and repairing errors in DNA. Variants affecting their function can have severe consequences since failure to repair damaged DNA can result in cells turning cancerous. Here, we compare germline and somatic variants in DDR genes, specifically looking at their locations in the corresponding three-dimensional (3D) structures, Pfam domains, and protein–protein interaction interfaces. We show that somatic variants in metastatic cases are more likely to be found in Pfam domains and protein interaction interfaces than are pathogenic germline variants or variants of unknown significance (VUS). We also show that there are hotspots in the structures of ATM and BRCA2 proteins where pathogenic germline, and recurrent somatic variants from primary and metastatic tumours, cluster together in 3D. Moreover, in the ATM, BRCA1 and BRCA2 genes from prostate cancer patients, the distributions of germline benign, pathogenic, VUS, and recurrent somatic variants differ across Pfam domains. Together, these results provide a better characterisation of the most recurrent affected regions in DDRs and could help in the understanding of individual susceptibility to tumour development.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Laskowski, Roman A 2
; Pons Tirso 3
; Thornton, Janet M 2
1 Spanish National Cancer Research Center (CNIO), Prostate Cancer Clinical Unit, Madrid, Spain (GRID:grid.7719.8) (ISNI:0000 0000 8700 1153); European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Cambridge, UK (GRID:grid.225360.0) (ISNI:0000 0000 9709 7726)
2 European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Cambridge, UK (GRID:grid.225360.0) (ISNI:0000 0000 9709 7726)
3 Spanish National Research Council (CNB-CSIC), Department of Immunology and Oncology, National Center for Biotechnology, Madrid, Spain (GRID:grid.4711.3) (ISNI:0000 0001 2183 4846)




